Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01928368 · ClinicalTrials.gov registry record · Phase 1
A First-in-Human, Double Blind, Single Dose Study in Healthy Subjects and Subjects With Mild Atopic Asthma.
A Phase 1 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
NCT01928368 is a Phase 1 study that has completed, run by Amgen. The registered enrollment target is 70 participants.
The verdict
NCT01928368, a Phase 1 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if a single dose of AMG 282 is safe in healthy subjects and subjects with mild atopic asthma.
Interventions
- DRUG AMG 282
- DRUG AMG 282 Matching Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2013-08 |
| Est. Completion | 2016-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01928368
The ClinicalTrials.gov registry entry for NCT01928368 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AMG 282 is the first listed.
NCT01928368 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01928368 about?
NCT01928368 is a clinical study titled "A First-in-Human, Double Blind, Single Dose Study in Healthy Subjects and Subjects With Mild Atopic Asthma.". The purpose of this study is to determine if a single dose of AMG 282 is safe in healthy subjects and subjects with mild atopic asthma.
What is the current status of trial NCT01928368?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2013-08. Estimated completion is 2016-03.
What interventions are being tested in trial NCT01928368?
The interventions under investigation include: AMG 282 (DRUG), AMG 282 Matching Placebo (DRUG).
Who is sponsoring clinical trial NCT01928368?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.